BioGend Therapeutics , Ltd. Receivables

The latest receivables for 6733.TWO is $63M as of June 2026. That compares with $50M in the prior-year period — up 25.4% year over year. Investors often review this figure alongside BioGend Therapeutics , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 6733.TWO's receivables moved from $50M to $63M — a 25.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioGend Therapeutics , Ltd.'s operating scale or balance-sheet position.

A receivables figure of $63M for 6733.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 6733.TWO's receivables ($63M), review year-over-year change from $50M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack BioGend Therapeutics , Ltd.'s receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.